Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.

Szczegóły
Abstrakt

Tytuł:: Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
Autorzy:: McGirr A; GSK, Mississauga, Canada. .
Van Oorschot D; GSK, Wavre, Belgium.
Widenmaier R; GSK, Mississauga, Canada.
Stokes M; Evidera, Saint-Laurent, Canada.
Ganz ML; Evidera, Waltham, MA, USA.
Jung H; Evidera, Waltham, MA, USA.
Varghese L; GSK, Singapore, Singapore.
Curran D; GSK, Wavre, Belgium.
Źródło:: Applied health economics and health policy [Appl Health Econ Health Policy] 2019 Oct; Vol. 17 (5), pp. 723-732.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Original Publication: Auckland, N.Z. : Open Mind Journals Ltd., c2002-
MeSH Terms:: Cost-Benefit Analysis*
Herpes Zoster/*prevention & control
Herpes Zoster Vaccine/*economics
Neuralgia, Postherpetic/*prevention & control
Vaccines, Attenuated/*economics
Aged ; Canada/epidemiology ; Female ; Herpes Zoster/epidemiology ; Humans ; Incidence ; Male ; Markov Chains ; Middle Aged ; Neuralgia, Postherpetic/epidemiology
References:: Ann Intern Med. 2015 Oct 6;163(7):489-97. (PMID: 26344036)
JAMA Intern Med. 2018 Feb 1;178(2):248-258. (PMID: 29297049)
BMJ Open. 2014 Jun 10;4(6):e004833. (PMID: 24916088)
Ther Adv Vaccines. 2015 Jul;3(4):109-20. (PMID: 26478818)
Pharmacoeconomics. 2009;27(12):991-1004. (PMID: 19908924)
MMWR Morb Mortal Wkly Rep. 2014 Aug 22;63(33):729-31. (PMID: 25144544)
Epidemiol Infect. 2001 Oct;127(2):305-14. (PMID: 11693508)
Hum Vaccin Immunother. 2019;15(4):765-771. (PMID: 30625011)
N Engl J Med. 2005 Jun 2;352(22):2271-84. (PMID: 15930418)
BMC Infect Dis. 2016 Oct 20;16(1):589. (PMID: 27765026)
Epidemiol Infect. 2000 Dec;125(3):651-69. (PMID: 11218215)
Vaccine. 2014 Mar 26;32(15):1745-53. (PMID: 24508036)
Hum Vaccin Immunother. 2017 Oct 3;13(10):2213-2221. (PMID: 28708959)
CMAJ. 2010 Nov 9;182(16):1731-6. (PMID: 20921251)
Clin Infect Dis. 2012 Apr;54(7):922-8. (PMID: 22291101)
N Engl J Med. 2016 Sep 15;375(11):1019-32. (PMID: 27626517)
Mayo Clin Proc. 2007 Nov;82(11):1341-9. (PMID: 17976353)
J Infect. 2018 May;76(5):475-482. (PMID: 29428228)
Can J Public Health. 2008 Sep-Oct;99(5):383-6. (PMID: 19009921)
Vaccine. 2018 Aug 9;36(33):5037-5045. (PMID: 30017145)
N Engl J Med. 2015 May 28;372(22):2087-96. (PMID: 25916341)
Neurology. 2013 Sep 3;81(10):928-30. (PMID: 23999562)
BMC Infect Dis. 2017 Jan 13;17(1):69. (PMID: 28086817)
Clin Infect Dis. 2015 Mar 15;60(6):900-9. (PMID: 25416754)
Am J Public Health. 2009 Oct;99 Suppl 2:S389-97. (PMID: 19797753)
BMC Geriatr. 2017 Jan 23;17(1):30. (PMID: 28114907)
Pain Res Manag. 2015 Jan-Feb;20(1):46-7. (PMID: 25664540)
BMC Infect Dis. 2014 Jul 20;14:402. (PMID: 25038799)
Pharmacoeconomics. 1999 Apr;15(4):369-76. (PMID: 10537955)
J Pain. 2010 Nov;11(11):1211-21. (PMID: 20434957)
Am J Manag Care. 2013 Jan;19(1 Suppl):S207-13. (PMID: 23448093)
Vaccine. 2016 Feb 3;34(6):863-8. (PMID: 26432913)
Hum Vaccin Immunother. 2019;15(1):34-44. (PMID: 30130448)
Contributed Indexing:: Local Abstract: [plain-language-summary] More than 95% of adults aged 50 are infected with varicella-zoster virus and are at risk of developing herpes zoster, also known as shingles. This risk is higher in older people and in people with a reduced immune system. Shingles causes a painful rash and may trigger persistent pain and other complications that greatly reduce quality of life. In Canada, Zostavax is the only existing approved vaccine against shingles. It has been offered in a publicly funded program in Ontario to those aged 65–70 years since September 2016. Shingrix, is a new shingles vaccine that has recently been approved by Health Canada for adults aged ≥ 50 years. The present model suggests that Shingrix confers higher protection against shingles compared to Zostavax, with a greater reduction in shingles episodes. The increase in vaccination costs would be partially offset by reduced healthcare visit and medication expenses. For these reasons, provincial health plans may consider offering Shingrix to people aged ≥ 50 years.
Substance Nomenclature:: 0 (Herpes Zoster Vaccine)
0 (Vaccines, Attenuated)
Entry Date(s):: Date Created: 20190629 Date Completed: 20200805 Latest Revision: 20200805
Update Code:: 20240104
PubMed Central ID:: PMC6748891
DOI:: 10.1007/s40258-019-00491-6
PMID:: 31250218
: Czasopismo naukowe

Full Text Finder

Objectives: In Canada, incidences of herpes zoster (HZ) and postherpetic neuralgia (PHN) are increasing, posing a significant burden on the healthcare system. This study aimed to determine the public health impact and cost effectiveness of an adjuvanted recombinant zoster vaccine (RZV) compared to no vaccination and to the live attenuated vaccine (ZVL) in Canadians aged 60 years and older.
Methods: A multi-cohort Markov model has been adapted to the Canadian context using recent demographic and epidemiologic data. Simulations consisted of age-cohorts annually transitioning between health states. Health outcomes and costs were discounted at 1.5% per year. The perspective of the Canadian healthcare payer was adopted. A coverage of 80% for the first RZV and ZVL dose and a compliance of 75% for the second RZV dose were assumed.
Results: RZV was estimated to be cost effective compared with no vaccination with an incremental cost-effectiveness ratio (ICER) of $28,360 (Canadian dollars) per quality-adjusted life-year (QALY) in persons aged ≥ 60 years, avoiding 554,504 HZ and 166,196 PHN cases. Compared with ZVL, RZV accrued more QALYs through the remaining lifetime and an increase in costs of approximately $50 million resulting in an average ICER of $2396. Results were robust under deterministic and probabilistic sensitivity analyses. HZ incidence rate and persistence of vaccine efficacy had the largest impact on cost effectiveness.
Conclusions: The cost-utility analysis suggested that RZV would be cost effective in the Canadian population compared with no vaccination and vaccination with ZVL at a willingness-to-pay threshold of $50,000.

Informacja